Market Overview:
The global immunology drug market is expected to grow at a CAGR of 7.8% from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of autoimmune diseases, increasing R&D expenditure by pharmaceutical companies, and growing demand for monoclonal antibodies (mAbs). However, the high cost of these drugs is likely to restrain the growth of this market during the forecast period. On the basis of type, the global immunology drug market can be segmented into monoclonal antibodies (mAbs), antibody drug conjugates (ADCs), interferon and cytokine therapies, and immunosuppressive medications. Monoclonal antibodies are expected to account for a major share of this market during the forecast period owing to their high efficacy in treating various autoimmune diseases. Antibody drug conjugates are also anticipated to witness significant growth during the forecast period due to their ability to target specific cells and tissues associated with various autoimmune diseases. On the basis of application, hospitals accounted for a major share of this market in 2017 owingtothe large numberof patients suffering from autoimmune diseases who require treatment with immunology drugs.
Product Definition:
Immunology Drug is a drug that is used to treat immunological diseases. Immunological diseases are diseases that are caused by problems with the immune system. The immune system is responsible for protecting the body from infection and disease. Immunology drugs help to improve the function of the immune system and help to treat immunological diseases.
Monoclonal Antibodies (mAb):
Monoclonal antibodies (mAbs) are antibody molecules, which are produced by the body's immune system to fight against bacteria, viruses or other harmful substances. The most common mAbs found in humans are those that bind to and inhibit the interleukin (IL) - receptor. These antibodies can also be obtained through genetic engineering techniques from cells of patients with a particular disease who have been treated with that disease's medication.
Antibody Drug Conjugates:
Antibody Drug Conjugates (ADC) are a group of drugs that bind to cancer cells and help the immune system to recognize and attack them. The first ADC approved was Antibody Drug Conjugate (ADC-1) in 2001 which was developed for breast cancer. Since then, many other ADCs have been developed for different types of cancers such as prostate, lung, head & neck, colorectal and breast cancer among others.
Application Insights:
The application segment is bifurcated into hospitals, clinics and cancer research centers and institutes. Hospitals are anticipated to remain the dominant revenue-generating segment over the forecast period owing to factors such as increasing prevalence of chronic diseases, growing geriatric population along with rising number of hospital beds in a country like India.
Clinics are expected to witness substantial growth during the forecast period due to an increase in demand for immunology drugs that target specific mechanisms of action on cells from a non-specific manner (to nonspecific effect). This has led to development of cost-effective treatment options for patients who would have been treated with monoclonal antibodies or other medication that had less specificity.
Regional Analysis:
North America dominated the global immunology drugs market in 2017. The presence of key players, favorable reimbursement policies, and increasing R&D activities are some of the factors responsible for its large share. In addition, rising incidence of cancer is also expected to drive this region’s growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to growing target population base and improving healthcare infrastructure in emerging countries such as China and India. Moreover, an increase in number of clinical trials being conducted across these countries will further boost revenue generation capacity during the forecast period.
Growth Factors:
- Increasing incidence of autoimmune diseases: The incidence of autoimmune diseases is increasing at an alarming rate across the globe. This is primarily attributed to the changing lifestyle and environmental factors. Immunology drugs help in treating these diseases and are thus expected to witness high demand in the coming years.
- Growing awareness about immunology drugs: There is a growing awareness among people about immunology drugs and their benefits in treating various autoimmune disorders. This is likely to boost the demand for such drugs in the near future.
- Rising R&D expenditure by pharmaceutical companies: Pharmaceutical companies are investing heavily in R&D activities for developing new and innovative immunology drugs. This is likely to fuel the growth of this market in the coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Immunology Drug Market Research Report
By Type
Monoclonal Antibodies (mAb), Antibody Drug Conjugates, Interferon and Cytokine therapies, Immunosuppressive medication
By Application
Hospitals, Clinics, Cancer Research Centers and Institutes
By Companies
Abbott Laboratories, Active Biotech, Eli Lilly and Company, Autoimmune Inc., Pfizer, GlaxoSmithKline plc, Seattle Genetics, Genentech, F. Hoffmann-La Roche Ltd., Eisai Co., Abbott Laboratories, Sanofi Aventis LLC.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
237
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Immunology Drug Market Report Segments:
The global Immunology Drug market is segmented on the basis of:
Types
Monoclonal Antibodies (mAb), Antibody Drug Conjugates, Interferon and Cytokine therapies, Immunosuppressive medication
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Cancer Research Centers and Institutes
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott Laboratories
- Active Biotech
- Eli Lilly and Company
- Autoimmune Inc.
- Pfizer
- GlaxoSmithKline plc
- Seattle Genetics
- Genentech
- F. Hoffmann-La Roche Ltd.
- Eisai Co.
- Abbott Laboratories
- Sanofi Aventis LLC.
Highlights of The Immunology Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Monoclonal Antibodies (mAb)
- Antibody Drug Conjugates
- Interferon and Cytokine therapies
- Immunosuppressive medication
- By Application:
- Hospitals
- Clinics
- Cancer Research Centers and Institutes
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Immunology Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
An immunology drug is a medication used to treat diseases or conditions that are caused by the body's immune system. Immunology drugs can be used to help the body fight infections, cancer, and other diseases.
Some of the major players in the immunology drug market are Abbott Laboratories, Active Biotech, Eli Lilly and Company, Autoimmune Inc., Pfizer, GlaxoSmithKline plc, Seattle Genetics, Genentech, F. Hoffmann-La Roche Ltd., Eisai Co., Abbott Laboratories, Sanofi Aventis LLC..
The immunology drug market is expected to register a CAGR of 7.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Immunology Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Immunology Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Immunology Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Immunology Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Immunology Drug Market Size & Forecast, 2020-2028
4.5.1 Immunology Drug Market Size and Y-o-Y Growth
4.5.2 Immunology Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Monoclonal Antibodies (mAb)
5.2.2 Antibody Drug Conjugates
5.2.3 Interferon and Cytokine therapies
5.2.4 Immunosuppressive medication
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Cancer Research Centers and Institutes
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Immunology Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Immunology Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Monoclonal Antibodies (mAb)
9.6.2 Antibody Drug Conjugates
9.6.3 Interferon and Cytokine therapies
9.6.4 Immunosuppressive medication
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Cancer Research Centers and Institutes
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Monoclonal Antibodies (mAb)
10.6.2 Antibody Drug Conjugates
10.6.3 Interferon and Cytokine therapies
10.6.4 Immunosuppressive medication
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Cancer Research Centers and Institutes
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Monoclonal Antibodies (mAb)
11.6.2 Antibody Drug Conjugates
11.6.3 Interferon and Cytokine therapies
11.6.4 Immunosuppressive medication
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Cancer Research Centers and Institutes
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Monoclonal Antibodies (mAb)
12.6.2 Antibody Drug Conjugates
12.6.3 Interferon and Cytokine therapies
12.6.4 Immunosuppressive medication
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Cancer Research Centers and Institutes
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Monoclonal Antibodies (mAb)
13.6.2 Antibody Drug Conjugates
13.6.3 Interferon and Cytokine therapies
13.6.4 Immunosuppressive medication
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Cancer Research Centers and Institutes
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Immunology Drug Market: Competitive Dashboard
14.2 Global Immunology Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abbott Laboratories
14.3.2 Active Biotech
14.3.3 Eli Lilly and Company
14.3.4 Autoimmune Inc.
14.3.5 Pfizer
14.3.6 GlaxoSmithKline plc
14.3.7 Seattle Genetics
14.3.8 Genentech
14.3.9 F. Hoffmann-La Roche Ltd.
14.3.10 Eisai Co.
14.3.11 Abbott Laboratories
14.3.12 Sanofi Aventis LLC.
